Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial

被引：0

作者：

Patrick NA Harris

Anton Y Peleg

Jon Iredell

Paul R Ingram

Spiros Miyakis

Andrew J Stewardson

Benjamin A Rogers

Emma S McBryde

Jason A Roberts

Jeff Lipman

Eugene Athan

Sanjoy K Paul

Peter Baker

Tiffany Harris-Brown

David L Paterson

机构：

[1] University of Queensland Centre for Clinical Research,School of Pathology and Laboratory Medicine

[2] Department of Infectious Diseases,Department of Infectious Diseases, School of Medicine

[3] The Alfred Hospital,Burns Trauma and Critical Care Research Centre

[4] Westmead Millenium Institute for Medical Research,Department of Infectious Disease, Barwon Health

[5] Westmead Hospital,Queensland Clinical Trials and Biostatistics Centre

[6] Department of Microbiology and Infectious Diseases,undefined

[7] Royal Perth Hospital,undefined

[8] University of Western Australia,undefined

[9] University of Wollongong and The Wollongong Hospital,undefined

[10] Department of Infectious Diseases,undefined

[11] Austin Health,undefined

[12] Monash Infectious Disease,undefined

[13] Monash Health,undefined

[14] Victorian Infectious Diseases Unit,undefined

[15] Royal Melbourne Hospital,undefined

[16] The University of Queensland,undefined

[17] Deakin University,undefined

[18] Clinical Trials & Biostatistics Unit,undefined

[19] QIMR Berghofer Medical Research Institute,undefined

[20] University of Queensland,undefined

来源：

Trials | / 16卷

关键词：

Extended-spectrum beta-lactamase; ESBL; Plasmid-AmpC; Therapy; Resistance; Beta-lactam/beta-lactamase inhibitor; Carbapenem; Clinical trial;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 148 条

[1]

Cohen J(2004)New method of classifying infections in critically ill patients Crit Care Med 32 1510-26

[2]

Cristofaro P(2008)Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern Lancet Infect Dis 8 159-66

[3]

Carlet J(2005)Extended-spectrum beta-lactamases: a clinical update Clin Microbiol Rev 18 657-86

[4]

Opal S(2011)Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins J Antimicrob Chemother 66 398-407

[5]

Pitout JD(2004)Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases Clin Infect Dis 39 31-7

[6]

Laupland KB(2012)Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis J Antimicrob Chemother 67 2793-803

[7]

Paterson DL(2012)beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts Clin Infect Dis 54 167-74

[8]

Bonomo RA(2012)Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study BMC Infect Dis 12 245-3

[9]

de Kraker MEA(2013)Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae Antimicrob Agents Chemother 57 5131-7

[10]

Wolkewitz M(2011)Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention Clin Infect Dis 53 60-94

← 1 2 3 4 5 6 7 8 9 10 →